The hsa-miR-125a/hsa-let-7e/hsa-miR-99b cluster is potentially implicated in Cystic Fibrosis pathogenesis Marie-Laure Endale Ahanda, Thierry Bienvenu,

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Bacterial contamination in the environment of hospitalised children with cystic fibrosis Agnès Ferroni, Aurélie Werkhauser-Bertrand, Muriel Le Bourgeois,

The prevalence of “risky behaviour” in adults with cystic fibrosis

Consequences of partial duplications of the human CFTR gene on cf diagnosis: Mutations or ectopic variations Ayman El-Seedy, Marie-Claude Pasquet, Thiery.

Treatment compliance in children and adults with Cystic Fibrosis

Analysis of the CFTR gene in Iranian cystic fibrosis patients: Identification of eight novel mutations Reza Alibakhshi, Roya Kianishirazi, Jean-Jacques.

The hsa-miR-125a/hsa-let-7e/hsa-miR-99b cluster is potentially implicated in Cystic Fibrosis pathogenesis Marie-Laure Endale Ahanda, Thierry Bienvenu,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.

Elevated levels of miR-145 correlate with SMAD3 down-regulation in Cystic Fibrosis patients Francesca Megiorni, Samantha Cialfi, Giuseppe Cimino, Riccardo.

Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function Fredrick Van Goor, Haihui Yu, Bill.

Splicing defects in the CFTR gene: Minigene analysis of two mutations, G>C and A>G Gwendal Dujardin, Diane Commandeur, Catherine Le Jossic-Corcos,

Cystic fibrosis: A new mutation in the Lebanese population

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

Abaigeal D. Jackson, Christopher H. Goss Journal of Cystic Fibrosis

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Spectrum of mutations in CFTR in Finland: 18 years follow-up study and identification of two novel mutations Satu Kinnunen, Sandra Bonache, Teresa Casals,

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection Marita Gilljam, Henrik Scherstén, Martin Silverborn, Bodil.

The ease of breathing test tracks clinical changes in cystic fibrosis

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation Shahid I. Sheikh, Frederick R. Long, Karen.

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Should diffuse bronchiectasis still be considered a CFTR-related disorder? Anne Bergougnoux, Victoria Viart, Julie Miro, Sébastien Bommart, Nicolas Molinari,

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Molecular detection of an atypical, highly resistant, clonal Pseudomonas aeruginosa isolate in cystic fibrosis patients Deirdre Keating, Mary J. Crowe,

Clinical presentation of mild cystic fibrosis in a Serbian patient homozygous for the CFTR mutation c G>A Aleksandra Nikolic, Nedeljko Radlovic,

Amyloidosis in cystic fibrosis: A case series

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Elisabeth P. Dellon, Elaine Chen, Jessica Goggin, Karen Homa, Bruce C

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy G. Fitch, K. Williams,

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Chee Y. Ooi, Peter R. Durie Journal of Cystic Fibrosis

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Kristoffer S. Berlin, Daniel A. Sass, W. Hobart Davies, Matthew D

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Gut dysbiosis in cystic fibrosis

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Absence of a gender gap in survival

Presentation transcript:

The hsa-miR-125a/hsa-let-7e/hsa-miR-99b cluster is potentially implicated in Cystic Fibrosis pathogenesis Marie-Laure Endale Ahanda, Thierry Bienvenu, Isabelle Sermet-Gaudelus, Laurent Mazzolini, Aleksander Edelman, Rima Zoorob, Noélie Davezac Journal of Cystic Fibrosis Volume 14, Issue 5, Pages 571-579 (September 2015) DOI: 10.1016/j.jcf.2015.02.011 Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 DNA sequences of the hsa-miR-125a/hsa-let-7e/hsa-miR-99b cluster in Cystic Fibrosis patients harbouring the DeltaF508-CFTR homozygous mutation. Sequences of pre-hsa-miR-99b, pre-hsa-let-7e and pre-hsa-miR-125a are shown in lower case with sequences of the mature sequence in bold. Three SNPs (boxed) named SNP1 (nt 52196076), SNP2 (nt 52196409) and SNP3 (nt 52196453) are identified in the region. Journal of Cystic Fibrosis 2015 14, 571-579DOI: (10.1016/j.jcf.2015.02.011) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Relative quantification of hsa-miR-125a, hsa-let-7e, and hsa-miR-99b by qRTPCR in pTracer, pTCFWT and pTCFDeltaF508 expressing HeLa cells. Journal of Cystic Fibrosis 2015 14, 571-579DOI: (10.1016/j.jcf.2015.02.011) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Identification of an RNA precursor consisting of hsa-miR-125a, hsa-let-7e and hsa-miR-99b. Journal of Cystic Fibrosis 2015 14, 571-579DOI: (10.1016/j.jcf.2015.02.011) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Supplementary Fig. S1 miR-28 and miR-125a are expressed in CFBE and CFPAC and HeLa cells. A and B quantitative RTPCR of miR-28 and miR-125a with CFBE and CFPAC RNA extracts enriched in small RNAs (<200nts). C quantitative RTPCR of miR-28 with the three different HeLa cell lines' total RNA extracts. Journal of Cystic Fibrosis 2015 14, 571-579DOI: (10.1016/j.jcf.2015.02.011) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Supplementary Fig. S2 Journal of Cystic Fibrosis 2015 14, 571-579DOI: (10.1016/j.jcf.2015.02.011) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Supplementary Fig. S3 Analysis of Bak, ErbB2, FGFR3 and Sirtuin7 quantities. (A) Immunoblot analysis of Bak and HSP60 was performed on pTracer, pTCFWT and pTCFDeltaF508 HeLa cell extracts. (B) Quantification in arbitrary units was performed with Image J using HSP60 as loading control (n=3). (C) Immunoblots of ErbB2 and actin were realised with pTracer, pTCFWT and pTCFDeltaF508 HeLa cell extracts. (D) Quantification in arbitrary units was performed with Image J using actin as loading control (n=5) *p<0.05 by Student's T test analysis. (E) Immunoblots of FGFR3 and actin were realised with pTRacer, pTCFWT and pTCFDeltaF508 HeLa cell extracts. (F) Quantification in arbitrary units was performed with Image J using actin as loading control (n=7). (G) Immunoblots of Sirtuin7 and actin were realised with pTRacer, pTCFWT and pTCFDeltaF508 HeLa cell extracts. (H) Quantification in arbitrary units was performed with Image J using actin as loading control (n=4). Journal of Cystic Fibrosis 2015 14, 571-579DOI: (10.1016/j.jcf.2015.02.011) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions